PharmaCyte Biotech is currently developing a treatment for type 1 diabetes that is unique among the treatments available for this disease. The company's treatment will also be available for those who have type 2 diabetes where traditional medications are no longer effective.
PharmaCyte Biotech is developing a treatment that encapsulates a human cell line (Melligen cells) designed to produce and store insulin and secrete it at levels proportional to the levels of glucose (blood sugar) in the human body. The encapsulation will be performed using PharmaCyte's cell-in-a-box® live cell encapsulation technology.
PharmaCyte Biotech believes that the combination of Melligen cells and Cell-in-a-Box® encapsulation technology could lead to an innovative treatment through the replacement of insulin-producing islet beta cells that will overcome all the problems of the past in the development of a true bio-artificial pancreas.
PharmaCyte has formed an International Diabetes Consortium composed of doctors, scientists and researchers from around the world to help you develop a successful treatment for diabetes.
We would like to thank Stock Market Media Group for documenting the company's diabetes history.
Images provided by:
University of Technology Sydney – UTS Science – Anna Zhu
Bay Colony Media
Video credits to PharmaCyte Biotech, Inc. YouTube channel